Inhibitor Therapeutics Past Earnings Performance
Past criteria checks 0/6
Inhibitor Therapeutics has been growing earnings at an average annual rate of 31.2%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
31.2%
Earnings growth rate
18.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -90.5% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Inhibitor Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -3 | 2 | 1 |
| 30 Jun 24 | 0 | -3 | 2 | 1 |
| 31 Mar 24 | 0 | -3 | 2 | 1 |
| 31 Dec 23 | 0 | -3 | 2 | 1 |
| 30 Sep 23 | 0 | 10 | 2 | 1 |
| 30 Jun 23 | 0 | 11 | 1 | 0 |
| 31 Mar 23 | 0 | 12 | 1 | 0 |
| 31 Dec 22 | 0 | 12 | 1 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 0 | 0 | 0 | 0 |
| 30 Sep 21 | 0 | -1 | 0 | 0 |
| 30 Jun 21 | 0 | -1 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
| 30 Sep 20 | 0 | -2 | 1 | 1 |
| 30 Jun 20 | 0 | -2 | 1 | 1 |
| 31 Mar 20 | 0 | -3 | 1 | 1 |
| 31 Dec 19 | 0 | -3 | 2 | 1 |
| 30 Sep 19 | 0 | -4 | 2 | 2 |
| 30 Jun 19 | 0 | -4 | 2 | 2 |
| 31 Mar 19 | 0 | -4 | 2 | 2 |
| 31 Dec 18 | 0 | -5 | 2 | 3 |
| 30 Sep 18 | 0 | -4 | 2 | 3 |
| 30 Jun 18 | 0 | -4 | 1 | 2 |
| 31 Mar 18 | 0 | -3 | 1 | 2 |
| 31 Dec 17 | 0 | -5 | 3 | 2 |
| 30 Sep 17 | 0 | -7 | 5 | 2 |
| 30 Jun 17 | 0 | -8 | 5 | 3 |
| 31 Mar 17 | 0 | -9 | 6 | 3 |
| 31 Dec 16 | 0 | -7 | 4 | 3 |
| 30 Sep 16 | 0 | -5 | 3 | 2 |
| 30 Jun 16 | 0 | -5 | 3 | 2 |
| 31 Mar 16 | 0 | -4 | 2 | 2 |
| 31 Dec 15 | 0 | -4 | 2 | 2 |
| 30 Sep 15 | 0 | -4 | 2 | 2 |
| 30 Jun 15 | 0 | -3 | 2 | 1 |
| 31 Mar 15 | 0 | -5 | 2 | 3 |
| 31 Dec 14 | 0 | -4 | 2 | 2 |
| 30 Sep 14 | 0 | -3 | 1 | 2 |
| 30 Jun 14 | 0 | -4 | 1 | 3 |
| 31 Mar 14 | 0 | -2 | 1 | 1 |
Quality Earnings: INTI is currently unprofitable.
Growing Profit Margin: INTI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: INTI is unprofitable, but has reduced losses over the past 5 years at a rate of 31.2% per year.
Accelerating Growth: Unable to compare INTI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: INTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: INTI has a negative Return on Equity (-90.54%), as it is currently unprofitable.